fda ban semaglutide The FDA's Decision to Compounds: What You Need to Know FDA Warns of Overdoses With

In the ATTAIN-1 clinical trial, people with obesity using Orforglipron lost -11.2% of their body weight on average over 72 weeks

For a deeper look at the biology behind these medications, see our guide on how GLP-1 actually works for weight loss

Retatrutides glucagon receptor activation may prove more effective for liver fat in such cases

There are other affordable pills available now, and new technology coming soon

Our preliminary research on people who completed our behaviour change programme alongside GLP-1 medication showed weight regain of only 3.2% at five months after stopping, compared to 6% or more in studies without structured habit support